A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


May 13, 2011

CVD Risk From Kaletra Might Be Lower Than Suspected

People taking a regimen containing Kaletra (lopinavir plus ritonavir) did have elevations in triglycerides, as has been reported in other studies, but they did not have a related increase in other measures of cardiovascular (CVD) risk. These data, which were published in the May issue of AIDS Research and Human Retroviruses, found that the greatest concerns for CVD—aside from triglyceride elevations—were factors not associated with Kaletra use.

CVD is a growing concern for people with HIV. Rates of heart attacks are on the rise, and experts predict they will continue to rise as more and more people with HIV enter their 50s and 60s. As a result, providers are looking for ways to limit their patients’ risk of CVD.

One potential risk factor that has received some attention is the role of specific antiretroviral (ARV) drugs in increasing CVD risk. In particular, protease inhibitors (PIs) have been found in some studies to increase the risk of heart attacks and other signs of CVD. This increased risk has been attributed to the fact that many of the older PIs caused significant increases in triglycerides and low-density lipoprotein (LDL) cholesterol, a lipid often called the “bad” cholesterol for its role in CVD risk.

Kaletra is one of the PIs known for some of the largest increases in triglycerides, and researchers and providers have therefore assumed it could also contribute to a higher risk for CVD. This led, in part, to the removal of the drug from the “preferred” category of ARVs to the “alternative” category in the U.S. Department of Health and Human Services (DHHS) HIV treatment guidelines.

To better understand the individual ways that Kaletra might contribute to CVD risk, Enos Bernasconi, MD, from the Hospital of Lugano in Switzerland, and his colleagues studied blood samples from 74 HIV-positive people enrolled in the Swiss HIV Cohort Study. Specifically, Bernasconi’s team looked at several measures of CVD risk: triglycerides and two types of low-density lipoprotein (LDL) cholesterol. Elevations in the two types of LDL they looked at—very-low-density lipoprotein (VLDL) and small dense LDL-apolipoprotein B-100 (sdLDL-apoB)—have been associated with a higher risk for CVD, particularly when found in combination with high triglycerides.

As has been found before, Kaletra therapy did result in an increase in triglycerides. In fact, more than one third (38 percent) had triglyceride levels higher than 150 milligrams per deciliter (mg/dl) in blood—a threshold beyond the point when CVD risk increases—before they ever started taking Kaletra. After beginning therapy, that number increased to 57 percent.

What Bernasconi and his colleagues also found, however, was that the elevations in triglycerides were not significantly associated with an increase in the two types of LDL cholesterol they measured. There was a small trend within the first year on treatment for an increase in sdLDL-apoB, but it was small enough that it could have occurred by chance and it diminished after the first year. According to the authors, this suggests that the impact of the increased triglyceride levels on CVD risk might be lower than has been assumed.

The study is small, and increases in triglycerides alone are a concern; however, the authors comment that other CVD risks are perhaps of equal or greater concern and should be monitored.

“The risk of cardiovascular events in our population remains a concern mainly due to the high percentage of patients with low HDL, frequent smoking and inflammatory factors associated with HIV infection,” they conclude.

Search: Kaletra, lopinavir, ritonavir, cardiovascular disease, CVD, triglycerides, low-density lipoprotein, very-low density lipoprotein, VLDL, LDL-apolipoprotein B-100, Enos Bernasconi, Hospital of Lugano, Switzerland

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.